#HVO hVIVO PLC – £5.2m RSV contract and Notice of Trading update January 4, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £5.2m contract with a global biotechnology company headquartered in Asia Pacific to test their respiratory syncytial virus (“RSV”) vaccine candidate, using hVIVO’s established RSV Human Challenge Study Model. The Company also announces that it will provide…

#ORPH Open Orphan plc – Positive in vitro results for FLU-v published September 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, Imutex Limited’s (“Imutex”) broad spectrum influenza vaccine, has been published in the scientific journal Vaccines.1 Previous clinical studies have demonstrated that FLU-v induced increased…

#ORPH Open Orphan – New Malaria Human Challenge Model Launched January 20, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials announces that further to the announcement on 9 August 2021, hVIVO, a subsidiary of Open Orphan, has inoculated the first cohort of volunteers with a GMP-manufactured malaria challenge agent as part of its first controlled human malaria infection (CHMI) challenge study. This study will assess CHMI using existing standard of…

Open Orphan #ORPH – Development of Controlled Human Malaria Infection Human Challenge Study August 9, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in testing vaccines and antivirals using human challenge clinical trials, announces that its subsidiary, hVIVO, has developed a Controlled Human Malaria Infection (“CHMI”) challenge model, both strengthening and further diversifying the Company’s world leading portfolio of viral challenge study models. The Malaria challenge model will assist in the advancement of antimalarial drug and vaccine candidates from November 2021. Results from…

#HVO hVIVO PLC – £5.2m RSV contract and Notice of Trading update January 4, 2023 – Posted in: Blog, hVIVO (HVO)

#ORPH Open Orphan plc – Positive in vitro results for FLU-v published September 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

#ORPH Open Orphan – New Malaria Human Challenge Model Launched January 20, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan #ORPH – Development of Controlled Human Malaria Infection Human Challenge Study August 9, 2021 – Posted in: Blog, Open Orphan (ORPH)

Address

Contact

Social

LEGAL